AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
1902 MAR 28 - (NewsRx.com & NewsRx.net) -- An osteoporosis drug marketed as an estrogen alternative may significantly lower the risk of heart attacks in postmenopausal women prone to heart disease, according to a study.
Moreover, the drug, called raloxifene and sold under the brand name Evista, does not raise the short-term, 1-year risk of heart attacks in such women - a danger seen in some studies of estrogen supplements.
The drug had no effect on the risk of heart trouble in healthy women, according to the study, which was funded by Evista manufacturer Eli Lilly and Co. Doctors and the company said it would be premature to use the drug to prevent heart problems.
Studies suggesting heart disease patients could face an increased risk of heart attacks in the first year of taking estrogen supplements have confounded patients and doctors, who for years have relied on research suggesting the supplements could help protect the heart.
The studies have heightened the dilemma millions of women face about whether to take menopause hormones, which can relieve symptoms such as hot flashes and protect bones but also have been linked to breast cancer when used for many years.
Company-funded research has suggested Evista reduces the risk of breast cancer and lowers bad cholesterol, but it also has been linked to blood clots and does not relieve symptoms of menopause.
Dr. Elizabeth Barrett-Connor of the University at California at San Diego led the new study, published in the February 20, 2002 Journal of the American Medical Association.